US Bancorp
- SEC CIK
- 0000036104
- Latest filing
- Aug 12, 2026
SGMOQ holding history
Sangamo Therapeutics, Inc in every 13F filed by US Bancorp, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
SGMOQ overviewAll 13F holders of SGMOQFull Q2 2026 holdings
- Shares (Q2 2026)
- 0
- Sold out in Q2 2026
- Value
- $0
- % of portfolio
- 0.0%
- Quarters held
- 19
- Since Q1 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q2 2026 | 0 | $0 | 0.0% | −11−100.0% | Sold out | Holders |
| Q1 2026 | 11 | $3 | <0.1% | 00.0% | Unchanged | Holders |
| Q4 2025 | 11 | $5 | <0.1% | 00.0% | Unchanged | Holders |
| Q3 2025 | 11 | $7 | <0.1% | 00.0% | Unchanged | Holders |
| Q2 2025 | 11 | $6 | <0.1% | 00.0% | Unchanged | Holders |
| Q1 2025 | 11 | $7 | <0.1% | −12−52.2% | Reduced | Holders |
| Q4 2024 | 23 | $23 | <0.1% | 00.0% | Unchanged | Holders |
| Q3 2024 | 23 | $20 | <0.1% | −512−95.7% | Reduced | Holders |
| Q2 2024 | 535 | $192 | <0.1% | +535 | New | Holders |
| Q4 2023 | 0 | $0 | 0.0% | −5,000−100.0% | Sold out | Holders |
| Q3 2023 | 5,000 | $3.00K | <0.1% | 00.0% | Unchanged | Holders |
| Q2 2023 | 5,000 | $6.50K | <0.1% | −6,113−55.0% | Reduced | Holders |
| Q1 2023 | 11,113 | $19.6K | <0.1% | +5,203+88.0% | Added | Holders |
| Q4 2022 | 5,910 | $18.6K | <0.1% | −2,374−28.7% | Reduced | Holders |
| Q3 2022 | 8,284 | $41.0K | <0.1% | −185−2.2% | Reduced | Holders |
| Q2 2022 | 8,469 | $35.0K | <0.1% | +328+4.0% | Added | Holders |
| Q1 2022 | 8,141 | $47.0K | <0.1% | +1,482+22.3% | Added | Holders |
| Q4 2021 | 6,659 | $50.0K | <0.1% | +1,024+18.2% | Added | Holders |
| Q3 2021 | 5,635 | $51.0K | <0.1% | −55−1.0% | Reduced | Holders |
| Q2 2021 | 5,690 | $68.0K | <0.1% | +690+13.8% | Added | Holders |
| Q1 2021 | 5,000 | $63.0K | <0.1% | – | – | Holders |
Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.